This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Naluzotan
DrugBank Accession Number
DB05562
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 450.64
Monoisotopic: 450.266462274
Chemical Formula
C23H38N4O3S
Synonyms
  • Naluzotan
External IDs
  • PRX-00023

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders and depression.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 1A
agonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Naluzotan is combined with 1,2-Benzodiazepine.
AcebutololNaluzotan may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Naluzotan is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when Naluzotan is combined with Acemetacin.
AcenocoumarolThe risk or severity of adverse effects can be increased when Naluzotan is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Naluzotan.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Naluzotan.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naluzotan.
AclidiniumNaluzotan may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Naluzotan is combined with Agomelatine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Acetanilides / N-acetylarylamines / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / Organosulfonamides / Organic sulfonamides / Acetamides / Aminosulfonyl compounds
show 7 more
Substituents
Acetamide / Acetanilide / Amine / Amino acid or derivatives / Aminosulfonyl compound / Anilide / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
LQ54E5B4EW
CAS number
740873-06-7
InChI Key
SPWZXWDPAWDKQE-UHFFFAOYSA-N
InChI
InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
IUPAC Name
N-(3-{4-[4-(cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
SMILES
CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1

References

General References
Not Available
ChemSpider
9605731
BindingDB
50187377
ChEMBL
CHEMBL209821
ZINC
ZINC000003963096
Wikipedia
Naluzotan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAnxiety Disorders1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentEpilepsies / Epilepsy, Localization Related / Temporal Lobe Epilepsy (TLE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0489 mg/mLALOGPS
logP2.68ALOGPS
logP2.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.08ChemAxon
pKa (Strongest Basic)7.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area81.75 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity127.77 m3·mol-1ChemAxon
Polarizability51.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr: Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi: 10.1097/JCP.0b013e31816774de. [Article]
  2. de Paulis T: Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Curr Opin Investig Drugs. 2007 Jan;8(1):78-86. [Article]
  3. Iyer GR, Reinhard JF Jr, Oshana S, Kauffman M, Donahue S: Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. J Clin Pharmacol. 2007 Jul;47(7):817-24. doi: 10.1177/0091270007300953. Epub 2007 May 10. [Article]

Drug created at November 18, 2007 18:26 / Updated at February 21, 2021 18:51